Skip to content
Open access

Automated Parallel Synthesis Accelerates Virtual Screening Hit Discovery

Jul 2026 · Journal of the American Chemical Society · Vol 148, pp. 29908 - 29920 · 0 citations · 70 references
Medicine

TL;DR

ComBINAUT is an automated parallel synthesis platform that generates diverse chemical scaffolds to accelerate hit validation and refinement, enabling the efficient exploration of chemical space and the rapid discovery of novel ligands.

Abstract

Virtual screening (VS) is a powerful approach to exploring a vast chemical space, encompassing libraries of millions to billions of compounds. However, the low hit rates of VS require testing numerous candidates to validate true binders, followed by iterative optimization cycles, which makes experimental validation costly and time-consuming. Here, we report COMBINAUT, an automated parallel synthesis platform that generates diverse chemical scaffolds to accelerate hit validation and refinement. Using a faculty-wide collection of in-house building blocks, the system enables enumeration of over 22.9 million compounds, each designed for parallelized synthesis within 32 h using repurposed solid-phase peptide synthesis equipment. Using this platform, we performed large-scale VS targeting the allosteric pocket of the immuno-oncology target, C–C chemokine receptor 2 (CCR2). Our approach facilitated the rapid synthesis and testing of 100 VS hits spanning diverse molecular architectures. In radioligand binding assays, we successfully validated nine hits with distinct scaffolds, including completely novel CCR2 ligand chemotypes. Iterative hit-to-lead optimization using the automated workflow produced cell-active CCR2 antagonists. This work demonstrates the synergy of automated synthesis and VS, enabling the efficient exploration of chemical space and the rapid discovery of novel ligands.

Read PDF

Similar papers

Open access Sep 2026

Pushing the boundaries of virtual screening scale of combinatorial spaces with the V-SYNTHES approach

The first application of the V-SYNTHES2 synthon-based screening approach to the 173-billion-compound Enamine xREAL Space is reported, demonstrating near-linear computational scaling with only a 10–15% increase in cost relative to the 11-billion-compound REAL Space.

Mykola V. Protopopov, Olha Semenenko, Maryna Vasylchuk et al. · 0 citations
Open access Sep 2026

AI-enhanced adaptive virtual screening of large libraries for ligand discovery.

AdaptiveFlow enables drug discovery at unprecedented scale and supports the development of AI-driven methods, and identifies nanomolar inhibitors of two disease-relevant targets, ferroptosis suppressor protein 1 and poly(ADP-ribose) polymerase 1.

Domiziana Cecchini, AkshatKumar Nigam, Ming Tang et al. · 1 citation
Aug 2026

Evaluating BioEmu-Generated Kinase Ensembles Reveals Structure Selection as the Virtual Screening Bottleneck.

It is shown that prospective structure selection, rather than structure generation, represents the primary bottleneck in ensemble-based VS, highlighting an urgent need for novel structural descriptors to identify high-performing conformations.

Jaeoh Shin, K. Joo, Jejoong Yoo · 1 citation
Open access Aug 2026

Integrated computational and automated flow synthesis platform for the rapid discovery of N-benzylpiperidine acetylcholinesterase inhibitors.

An integrated platform that couples ensemble virtual screening, automated continuous-flow library synthesis with inline scavenging, and biological profiling is benchmarked, allowing the rapid generation of first-round leads in early-stage medicinal chemistry.

A. Reinhardt, A. Theron, Asongwe Lionel Ateh Tantoh et al. · 0 citations
Jul 2026

Real-World Assessment of Machine-Learned Docking Using Bioassay-Derived Benchmarks

This work systematically evaluates the performance of a popular ML-based docking method, DiffDock-Pocket, on high-throughput screening (HTS) data sets derived from the PubChem BioAssay database, a premier source of bioactivity data.

Furyal Ahmed, M. Soellner, Charles L. Brooks · 0 citations
#generative ai Review Sep 2026

Machine Learning‐Aided Small‐Molecule Virtual Screening: Recent Advances and Future Perspectives

A comprehensive review of how Artificial Intelligence and Machine Learning are redefining this landscape across three critical dimensions outlines the transition toward end‐to‐end, adaptive discovery systems that ensure computational hits are biologically potent, structurally optimized, and synthetically accessible.

Yi-Fei Wang, Nupur Bansal, Shiyun Wa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.